SS-31
Elamipretide, a mitochondria-targeted tetrapeptide that binds cardiolipin and stabilises the inner membrane.
How it works
Selectively concentrates in the inner mitochondrial membrane, preserves cristae structure, and improves electron-transport-chain efficiency.
Reported benefits
- Improved skeletal-muscle bioenergetics in older adults
- Benefit in primary mitochondrial myopathies in trials
- Investigated for Barth syndrome and dry AMD
Dosage & administration
Trials used 40 mg subcutaneously daily.
Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.
Clinical & pre-clinical evidence
Elamipretide in primary mitochondrial myopathy
Neurology · 2018
Improved 6-minute walk distance vs placebo over 4 weeks.
Safety & warnings
- Injection-site reactions most common
- Mild GI symptoms in some studies
For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.
Available presentations
10 mg
2S10
Box of 10 · $315
Single vial · $630
50 mg
2S50
Box of 10 · $1,230
Single vial · $2,460
Related guides
Semax
A Russian heptapeptide derived from ACTH(4-10) with neuroprotective and pro-cognitive activity.
Selank
A synthetic tuftsin analogue with anxiolytic, nootropic, and immunomodulatory effects.
DSIP
Delta Sleep-Inducing Peptide, a nonapeptide identified in cerebral venous blood of rabbits during sleep.